U.S. markets close in 24 minutes
  • S&P 500

    4,454.31
    +58.67 (+1.33%)
     
  • Dow 30

    34,801.81
    +543.49 (+1.59%)
     
  • Nasdaq

    15,068.26
    +171.41 (+1.15%)
     
  • Russell 2000

    2,259.67
    +41.11 (+1.85%)
     
  • Crude Oil

    73.14
    +0.91 (+1.26%)
     
  • Gold

    1,749.90
    -28.90 (-1.62%)
     
  • Silver

    22.61
    -0.30 (-1.30%)
     
  • EUR/USD

    1.1748
    +0.0052 (+0.45%)
     
  • 10-Yr Bond

    1.4100
    +0.0740 (+5.54%)
     
  • GBP/USD

    1.3731
    +0.0111 (+0.82%)
     
  • USD/JPY

    110.2660
    +0.4880 (+0.44%)
     
  • BTC-USD

    44,729.90
    +1,308.58 (+3.01%)
     
  • CMC Crypto 200

    1,120.85
    +11.92 (+1.08%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Icon: Q2 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Icon (NASDAQ:ICLR) were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share fell 28.99% year over year to $1.20, which beat the estimate of $1.10.

Revenue of $620,228,000 decreased by 10.78% from the same period last year, which beat the estimate of $598,770,000.

Looking Ahead

Q3 EPS expected between $6.00 and $6.50.

View more earnings on ICLR

Q3 revenue expected between $2,650,000,000 and $2,750,000,000.

Price Action

Company's 52-week high was at $194.17

Company's 52-week low was at $104.28

Price action over last quarter: Up 27.64%

Company Profile

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.